The Evolving Childhood Vaccine Schedule: Staying Atop the Shifting Vaccine Recommendations

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

Deborah Fuller, PhD, provides commentary around the data, and advantages of the technology.

Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.

The 2026 Antimicrobial Resistance Threats Report from the CDC categorizes 19 bacterial and fungal pathogens by level of threat to health in the US.

A CDC analysis of Antimicrobial Resistance Laboratory Network data found pediatric carbapenemase-producing CRE incidence in the United States rose 92% from 2019 to 2024, driven mostly by NDM-producing organisms.

Here is a case that was linked to a unique travel history and led to a series of acute health issues.

Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.

CDC reports 10,772 confirmed Ebola cases and 5234 deaths, making this the second-largest outbreak on record. Kenya and Nigeria have reported cases.